This content is in French.
Epigenetics and angiogenesis in the tumor microenvironment
11 mars 2024
In the randomized Phase 2 trial, investigators studied the efficacy of combining the monoclonal antibody sintilimab with the histone deacetylase inhibitor chidamide (HDACi) with or without the monoclonal antibody bevacizumab in patients…
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Feng Wang et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024 Mar 4.
View the source
